Journal of nephrology & therapeutics最新文献

{"title":"Acute Kidney Injury and Rhabdomyolysis","authors":"V. Mamidi, M. Shekar","doi":"10.37421/JNT.2020.10.343","DOIUrl":"https://doi.org/10.37421/JNT.2020.10.343","url":null,"abstract":"Background and objectives: Rhabdomyolysis is clinical syndrome characterized by breakdown of skeletal muscle and the release of intracellular contents into the circulation. Acute kidney injury (AKI) is one of the common systemic complication of rhabdomyolysis. The aim of the study is to report the varied aetiologies of rhabdomyolysis and to study their presentation, clinical profile and outcome in patients with AKI. Methods: Sixty-four patients are identified with rhabdomyolysis over a period of one year and out of them AKI was seen in 24 patients (37.5%%). The association of rhabdomyolysis and AKI was studied retrospectively in eight patients based on the data in our charts. One patient from different aetiologies of rhabdomyolysis leading to AKI was taken to report the varied aetiologies and presentation of rhabdomyolysis. Hence, eight patients included in the study. Data was expressed as median. Results: Our results show that AKI associated with rhabdomyolysis was related with comorbidity in all cases (bacterial sepsis, statin induced, chemotherapy induced, herbicide poisoning, cocaine abuse, road traffic accident, strenuous exercise, metabolic myopathy). Most common presenting symptom was myalgia followed by oliguria. Maximum median serum creatinine was 4.7 mg/dl before treatment and 1.7 mg/dl after treatment. Maximum median creatine phosphokinase levels was 2451 IU/L before treatment and 262 IU/L after treatment. Treatment given for rhabdomyolysis and acute kidney injury include either conservative treatment with adequate hydration and alkaline diuresis or invasive treatment such as renal replacement therapy or both. All the patients were treated with hydration and six patients required haemodialysis during hospital stay. Serum creatinine fell simultaneously with the decrease in creatine phosphokinase levels in all cases. Conclusion: In conclusion, rhabdomyolysis is an uncommon and preventable cause of AKI. It is caused by varied aetiologies, hence high index of suspicion regarding rhabdomyolysis is required in patients with AKI. The presence of rhabdomyolysis associated with AKI is indicative of the presence of comorbidity, as observed in all eight patients studied here. There was an improvement of renal function in all cases as creatine phosphokinase levels decreased. Hence, timely intervention is required to prevent adverse outcomes in rhabdomyolysis.","PeriodicalId":89981,"journal":{"name":"Journal of nephrology & therapeutics","volume":"10 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70055368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased Neutrophil to Lymphocyte Ratio(NLR) is a Sign of Disease Activity inSystemic Lupus Erythematosus Patientswith Renal Involvement","authors":"N. Bilen, E. Çankaya, Y. Bilen, A. Uyanık, F. Erdem","doi":"10.37421/JNT.2020.10.344","DOIUrl":"https://doi.org/10.37421/JNT.2020.10.344","url":null,"abstract":"Systemic lupus erythematosus (SLE) is an idiopathic multi-systemic autoimmune disease that covers a wide array of clinical and laboratory findings. Neutrophil to lymphocyte ratio (NLR) is a simple onsite available recently emerged inflammatory marker which is evaluated in different inflammatory conditions such as infection, athero-embolic disease, malignancies and autoimmune disease. In this study we aimed to investigate any relation between disease activity and NLR of the SLE patients with renal involvement. In this study we retrospectively analyzed hematological and laboratory parameters of SLE patients with renal involvement during both in active disease and in remission period. We investigated 36 SLE patients with renal involvement in their active and remission period of the disease. Mean proteinuria and serum albumin level of the patients at active disease period were 5.26 ± 2.92 gr/day, 2.58 ± 0.71 gr/dl in orderly. Mean proteinuria and serum albumin level of the patients at remission period after cessation of intensive immunosuppression were 0.77 ± 1.59 gr/day, 4.08 ± 0.58 gr/dl inorderly. Mean NLR at active disease period of the patients was statistically significantly detected higher than at remission period (6.11 ± 5.89, 2.65 ± 1.53, p=0.00). We detected that SLE patients with renal involvement has a high NLR during disease activation and statistically significantly lower NLR at remission period. We offer to investigate NLR as a disease activity marker for SLE patients with renal involvement via prospective randomized large scaled studies.","PeriodicalId":89981,"journal":{"name":"Journal of nephrology & therapeutics","volume":"10 1","pages":"1-4"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70061810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevention of renal pathology","authors":"pMargaret Williamsp","doi":"10.4172/2161-0959-C7-068","DOIUrl":"https://doi.org/10.4172/2161-0959-C7-068","url":null,"abstract":"","PeriodicalId":89981,"journal":{"name":"Journal of nephrology & therapeutics","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70543014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of hypertension in children and adolescence","authors":"pMazen Abou Chaabanp","doi":"10.4172/2161-0959-C5-062","DOIUrl":"https://doi.org/10.4172/2161-0959-C5-062","url":null,"abstract":"","PeriodicalId":89981,"journal":{"name":"Journal of nephrology & therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70542263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrent Urinary Tract Infection Revealing an Acquired Para-Ureteral Diverticulum after Renal Transplantation: Case Study","authors":"Omar Jendouzi, A. Sobhi, Abdelali Bahadi, M. Alami, D. Elkabbaj, A. Ameur","doi":"10.37421/jnt.2019.9.335","DOIUrl":"https://doi.org/10.37421/jnt.2019.9.335","url":null,"abstract":"of renal to iliac drainage a ureteroneocystostomy a Abstract Renal transplantation (RT) is considered to be the best substitute treatment for end-stage renal failure. Urologic complications occur in 4% to 8%. A delay in detection and treatment of any of these complications may lead to loss of renal graft function, morbidity of patients. One of the most frequent complication is Vesico Ureteral Reflux. We report a case of a young transplant patient, presented with a singular complication of RT: grade III vesicoureteral reflux associated to an acquired postoperative paraureteral diverticulum, discussing the clinical and therapeutic aspects of this complication.","PeriodicalId":89981,"journal":{"name":"Journal of nephrology & therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70054566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Epicardial Fat Tissue at Cardiovascular Risk Assessment in Hemodialysis Patients with Nutritional Disorder","authors":"M. Demir, Omer Canpolat, A. Cerci, A. Doğukan","doi":"10.37421/jnt.2019.9.338","DOIUrl":"https://doi.org/10.37421/jnt.2019.9.338","url":null,"abstract":"Patients with ESRD receiving HD treatment have been 2075% PEM [1,2]. This can be result from factors such as uremia, inflammation, multiple drug use, physical barriers, dietary restrictions, gastrointestinal system disorders, metabolic acidosis or HD therapy itself [2]. In this population it is important to assess nutritional status and body composition correctly. Because protein-energy malnutrition is the strongest risk factor for morbidity and mortality [1,3,4].","PeriodicalId":89981,"journal":{"name":"Journal of nephrology & therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70055175","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does Omega-3 Supplementation have Beneficial Effects on Blood Pressure, Left Ventricular Geometry and Arterial Function and Arterial Properties in Patients with Chronic Renal Disease Stage 1-3?","authors":"A. Pluta, P. Stróżecki, J. Kęsy, M. Krintus, B. Sulikowska, G. Odrowąż‐Sypniewska, J. Manitius","doi":"10.37421/jnt.2019.9.323","DOIUrl":"https://doi.org/10.37421/jnt.2019.9.323","url":null,"abstract":"Background: Chronic kidney disease (CKD) is characterized by unfavorable cardiac and vascular remodeling. The study aimed at evaluating effects of 6-month supplementation with omega-3 on blood pressure, left ventricular geometry and function, and arterial properties in patients with CKD 1-3. Methods: Six-month supplementation with omega-3 acids (2 g/day) was completed in 87 CKD patients, and in 27 individuals without CKD, hypertension or overt cardiovascular disease. At baseline and after supplementation, an echocardiographic examination was performed, evaluating left ventricular mass index (LVMI), left ventricular relative wall thickness (RWT), and ejection fraction (EF). Ultrasound imaging of the common carotid artery with intima media thickness (IMT), aortic pulse wave velocity measurement (PWV) and 24-hour blood pressure monitoring (ABPM) were performed. Serum concentration of omega-3 acids: eicosapentaenoic (EPA), docosahexaenoic (DHA), and alpha linolenic (ALA) was determined using gas chromatography. Results: After six-month omega-3 supplementation, ALA concentration increased in CKD patients and in reference group, while EPA and DHA did not change. PWV and IMT values did not change significantly. Posterior wall thickness (PWd) (p=0.018) and RWT decreased (p=0.035), while LVMI and EF did not change in CKD group. ABPM did not change. Conclusion: Supplementation with omega-3 acid resulted in beneficial left ventricular remodeling, despite the absence of changes in ABPM and arterial properties. Trial registration: The study was registered in Clinical Trials.gov. Identifier: NCT 02147002.","PeriodicalId":89981,"journal":{"name":"Journal of nephrology & therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70054663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug Treatment in Non-Dialysed Chronic Renal Failure Patients in Senegal (West Africa)","authors":"M. Cisse, M. S. Diawara, Y. Kane, K. Fall, A. Lemrabott, Fayed Ma, P. Diallo, M. Faye, F. Ka, A. Niang, B. Diouf","doi":"10.37421/jnt.2019.9.339","DOIUrl":"https://doi.org/10.37421/jnt.2019.9.339","url":null,"abstract":"Chronic renal failure (CRF) is defined as the persistence for more than 3 months of renal impairment and/or a decrease of glomerular filtration rate (GFR) <60 ml/min/1.73 m2 of corporal surface [1,2]. The prevalence of moderate CKD is estimated at 6.5% in Switzerland, 7.7% in the United States and 8.1% in France [3-5]. According to a study conducted in Switzerland in 2014, only 45.1% [3] of patients had a drug treatment in conformity with the recommendations. However, studies around the world have concluded that there is a need to optimize the treatment of patients with CKD [6-11]. In Senegal, no study has been conducted on drug prescription in chronic renal failure patients. Based on this observation, we conducted this study to analyze drug prescriptions in patients with non-dialysis CKD in order to deduce the factors of progression of the CKD and the occurrence of deaths related to drug prescribing.","PeriodicalId":89981,"journal":{"name":"Journal of nephrology & therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70055257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transient Pseudohypoaldosteronism in Childrens Secondary to Urinary Tract Infection: Literature Review and Report of 2 Cases","authors":"N. S, N. H, M. J, Soboh S, E. N, Shhadi S, Boshra N, N. W","doi":"10.37421/jnt.2019.9.340","DOIUrl":"https://doi.org/10.37421/jnt.2019.9.340","url":null,"abstract":"Primary pseudohypoaldosteronism (PHA-I) is considered a heterogeneous syndrome and characterized by salt loss due to nonresponse to target organs for mineralocorticoids. Heredity is usually autosomal dominant, and in some cases is also recessive or sometimes mutated [1,2]. Since primary pseudohypoaldosteronism type 1 (PHA1) was first described, which is the classic form, and PHA type II (PHAII), which is also referred to as Gordon syndrome or chloride shunt syndrome.","PeriodicalId":89981,"journal":{"name":"Journal of nephrology & therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70055300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contribution of an Interferon Gamma Released Assay to the Detection of Latent Tuberculosis in Chronic Dialysis Patients in Sub-Saharan Africa","authors":"A. Lemrabott, M. Faye, M. Faye, Y. Kane, M. Moustapha Cisse, K. Fall, Alex Ismaël Keita, M. Mbengue, N. Keita, B. Ba, S. Diagne, E. F. Fary Ka, A. Niang, B. Diouf","doi":"10.37421/jnt.2019.9.327","DOIUrl":"https://doi.org/10.37421/jnt.2019.9.327","url":null,"abstract":"Introduction: Tuberculosis (TB) is common in patients with chronic renal failure due to their immunosuppressed state. Diagnosing TB is difficult because of the latency of the clinical and biological picture. This study was conducted to assess the performance of the Interferon Gamma Released Assay (IGRA) in the diagnosis of latent TB infection in chronic dialysis patients in Senegal. Materials and methods: This is a cross-sectional study carried out in Nephrology Department of Aristide Le Dantec University Hospital during 6 month. All patients with chronic haemodialysis or chronic peritoneal dialysis were included. A group of patients with non-dialyzed kidney disease was also included. Patients with active TB at the time of the study were not included. A tuberculin skin test (TST) and an IGRA were performed. The QuantiFERON® (QFT) was repeated 3 months later in the group of dialysis patients. Results: Sixty-two patients were included: 22 haemodialysis (HD) patients, 19 peritoneal dialysis (PD) patients and 21 patients with non-dialyzed kidney disease (NDKD). The mean age was 44 ± 12 years with a sex ratio M/F of 1.06. Nineteen patients were vaccinated with BCG. TST was positive in 22 patients (35.4%). Subjects with a positive TST had a significantly higher rate of BCG vaccination (P=0.002) than those with a negative TST. QFT was positive in 17 patients (28%) and undetermined in 9 patients (14%). In patients with a positive QFT, six (27%) were in HD, four (21%) in peritoneal dialysis and seven (33%) in NDKD. A total of 9/17 (52%) QFT-positive patients developed active TB. Correlation (r=0.998, p=0.001) indicates that T cell functionality was not affected by the duration of renal replacement therapy. Conclusion: These results highlight the advantage of Quantiferon test over TST for diagnosis of latent TB in immunocompromised patients, including chronic dialysis patients.","PeriodicalId":89981,"journal":{"name":"Journal of nephrology & therapeutics","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"70054755","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}